Abstract:Abstract BACKGROUND: Immune checkpoint inhibitors (ICIs) have marked therapeutic effects in many cancer patients. This is not the case for the large majority (~85%) of colorectal cancers (CRC), i.e. those classified as microsatellite stable (MSS) tumors. Cancers that do not respond to immunotherapies, such as this predominant CRC form, have a T cell non-infiltrated phenotype and are known as “cold” tumours. They are poorly immunogenic, as opposed to ICI-responsive “hot” tumours that are associated with high T cell infiltration. A typical immunosuppressive mechanism used by tumors is the production of prostaglandin E2 (PGE2), which binds four EP receptor subtypes on tumor and immune cells to promote tumor survival. The EP4 receptor plays a major role in PGE2-induced immunosuppression. CR6086 is a clinical stage EP4 receptor antagonist acting as a targeted immunomodulator. This study tested the hypothesis that the EP4 antagonist CR6086 could turn cold into hot tumors, favoring the response to ICI therapy. METHODS: We investigated the efficacy of combining CR6086 with an ICI (i.e. anti-mouse PD-1 (CD279), clone RMP1-14 [mAb]) in a syngeneic model of CRC resistant to ICI therapy. CT26 colon carcinoma cells (1 × 106) were inoculated subcutaneously in the right flank of female BALB/c mice. Treatments started on day 7 post-inoculation, when all tumors were within the target volume range of 50-100 mm3. CR6086 (30 mg/kg) was administered orally once daily for 14 days (QDx14); anti-PD-1 mAb (150 μg/mouse) was administered intraperitoneally on days 7, 10, 14 and 17. RESULTS: The combination of CR6086 and anti-PD-1 significantly decreased tumor growth vs vehicle-treated mice (mean tumor volume: 721±166 mm3 vs 1457±219 mm3; P&lt;0.05, Two-way RM ANOVA followed by Dunnett's test, n=11/group), as measured after 14 days of treatment. The anti-PD-1 alone did not affect tumor progression, similarly to CR6086 monotherapy. RT-PCR analysis on tumor tissues showed that combined treatment increased (≥2-fold change) the gene expression of key factors for lymphocyte recruitment and activation. They include specific chemokines (CCL4, CCL5, CXCL10) responsible for increased T cell and dendritic cell infiltrate; CD8α, a major indicator for the presence of cytotoxic T lymphocytes; the antigen processing marker H2-Eb1s; INFγ, a T cell activation factor; TNFα, a cytokine produced by M1 macrophages and involved in tumor cell death; PD-L1, a prognostic biomarker with predictive value for the response of patients under anti-PD-1 therapy. These findings on gene expression are well reflected at the cellular level, because combined treatment increased general and T cell infiltrate, as assessed by haematoxylin/eosin staining and CD3+ immunohistochemistry. Conversely, the combination of CR6086 and anti-PD-1 reduced the gene expression of MMP-9, a matrix metalloproteinase involved in tumor growth, invasion, metastasis, extracellular matrix remodeling, and angiogenesis. CONCLUSION: These results suggest that the EP4 receptor antagonist CR6086 may turn a cold MSS murine colorectal cancer, non-responsive to ICI treatment, into a hot tumor responsive to ICIs. Citation Format: Gianfranco Caselli, Flora Ferrari, Tiziana Piepoli, Adriana Grotti, Rosanna Cavagnoli, Giuseppe M. Montagna, Pierpaolo Romanelli, Albino Bonazzi, Marco Lanza, Camilla Recordati, Lucio C. Rovati. Combination of the EP4 antagonist CR6086 and anti-PD-1 monoclonal antibody inhibits tumor growth in a microsatellite stable colorectal cancer in mice [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2208.

Abstract 4082: Anchored IL-12 synergizes with an epigenetic modulator to promote immune remodeling and overcome anti-PD1-refractory murine tumors

Abstract 4065: Entinostat synergizes with the IL-15 superagonist N-803 and anti-PD-1 to engage cDC1 and stem-like TCF-1+ CD8+ T and NK cells to overcome colorectal tumors refractory to anti-PD-1 therapy

Abstract 5515: Combination of recombinant murine IL-12 and anti-PD-1 induced synergistic anti-tumor response

Abstract 1425: Epigenetic modulation synergizes with a novel TCR β chain directed antibody-fusion molecule to suppress checkpoint-refractory tumors irrespective of MHC I status

Alum-anchored IL-12 combined with cytotoxic chemotherapy and immune checkpoint blockade enhanced antitumor immune responses in head and neck cancer models

Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape

Abstract 6522: Epigenetic modulation decreases myeloid suppression to improve response to immune checkpoint inhibition in breast cancer

Abstract 2359: New insights into targeting the CD200R1 pathway in T and NK cells using 23ME-00610 as a single agent or in combination

Abstract 2713: Novel anti-PD-L1-IL-15 diabody immunocytokine in combination with radiation therapy improves response rates in immune-resistant murine head and neck cancer

Abstract 4058: Nanoparticle delivery of interleukin-2 induces anti-tumor immune response and therapeutic efficacy in mouse tumor models

Abstract 3535: Simultaneous inhibition of Axl and MerTK enhances anti-PDL1 efficacy and creates a pro-inflammatory tumor immune microenvironment in head and neck cancer

Abstract 2053: Spatiotemporal tumor immune modulation by localized delivery of cancer therapeutics using an implantable microdevice

Abstract LB119: The immune-modulation of HM16390, firing up the poor tumor microenvironment to induce a potent anti-tumor efficacy

Abstract 4043: Nanoparticle-mediated combination therapy to synergistically harness Type I interferons and senescence in the pancreatic tumor microenvironment

Abstract 4066: Generation of tumor targeted self-assembling split IL-12 subunits for the treatment of cancer

Abstract LB438: Preclinical characterization of ONM-412, an ultra-pH sensitive nanoparticle encapsulated IL-12 fusion protein

Abstract 7240: Intratumor delivery of plasmid DNA encoding immune stimulating agents induces both local and systemic responses

Abstract 2721: Sustained delivery of low-dose anti-CTLA-4 by genetically engineered encapsulated cells to the tumor microenvironment drives tumor response and prolongs survival in a colorectal cancer model

Abstract 2208: Combination of the EP4 antagonist CR6086 and anti-PD-1 monoclonal antibody inhibits tumor growth in a microsatellite stable colorectal cancer in mice

Abstract 719: A tumor-activated PD1/IL2 bispecific molecule, designed to overcome IL-2 receptor-mediated clearance, improve tolerability and stimulate antigen-experienced CD8+ T cells in the tumor microenvironment of murine models

Abstract 2361: A PD1-antibody-attenuated IL-2 fusion protein activates immune cells leading to the inhibition of tumor growth in ex vivo human 3D tumor models